Copyright
©The Author(s) 2022.
World J Psychiatry. Jan 19, 2022; 12(1): 140-150
Published online Jan 19, 2022. doi: 10.5498/wjp.v12.i1.140
Published online Jan 19, 2022. doi: 10.5498/wjp.v12.i1.140
All patients (n = 101) | Severe (n = 17) | Non-severe (n = 84) | F/χ2 | P | |
Age | 54.8 ± 12.0 | 61.3 ± 14.1 | 53.4 ± 11.2 | 9.63 | 0.003 |
Median (IQR), years | 56 (48-63) | 65 (57-70) | 55 (47-61) | ||
Distribution, years (%) | 14.50 | 0.001 | |||
20-49 | 30 (29.7%) | 2 (11.8%) | 28 (33.3%) | ||
50-64 | 51 (50.5%) | 6 (35.3%) | 45 (53.6%) | ||
≥ 65 | 20 (19.8%) | 9 (52.9%) | 11 (13.1%) | ||
Male/female | 72/29 (71.3%/28.7%) | 10/7 (58.8%/41.2%) | 62/22 (73.8%/26.2%) | 1.55 | 0.21 |
Blood pressure | |||||
Systolic pressure | 122.2 ± 7.2 | 119.6 ± 6.8 | 122.8 ± 7.2 | 2.80 | 0.09 |
Diastolic pressure | 77.2 ± 5.5 | 76.9 ± 4.4 | 77.2 ± 5.7 | 0.06 | 0.81 |
Diagnosis | |||||
Schizophrenia | 84 | 10 | 74 | ||
Bipolar disorder | 4 | 1 | 3 | ||
Alzheimer’s Disease | 4 | 4 | 0 | ||
Mental retardation | 3 | 1 | 2 | ||
Epileptic psychosis | 3 | 0 | 3 | ||
Organic mental disorder | 3 | 1 | 2 | ||
Weight (kg) | 62.1 ± 10.3 | 55.8 ± 7.7 | 63.2 ± 10.4 | 1.62 | 0.21 |
Smoker/non-smoker | 14/76 | 1/10 | 13/66 | 0.40 | 0.53 |
Duration of illness (yr) | 27.9 ± 11.8 | 31.7 ± 14.4 | 27.4 ± 11.4 | 1.41 | 0.24 |
Age of onset (yr) | 26.9 ± 11.0 | 34.3 ± 17.5 | 25.8 ± 9.4 | 2.56 | 0.11 |
Comorbid physical diseases | 43 (48.8%) | 13 (76.5%) | 40 (47.6%) | 4.72 | 0.03 |
Antipsychotics | |||||
Clozapine | 14 (13.9%) | 3 (17.6%) | 11 (13.1%) | 0.25 | 0.62 |
Non-clozapine | 87 (86.1%) | 14 (82.4%) | 73 (86.9%) | ||
Antipsychotic dose (mg) (chlorpromazine equivalents) | 239.2 ± 156.2 | 191.0 ± 164.1 | 264.4 ± 160.8 | 3.16 | 0.08 |
COVID-19 patients (n = 84) | Non-COVID-19 patients (n = 174) | F, Z or χ | P | |
Age (yr) | 54.6 ± 9.5 | 51.1 ± 9.5 | 7.65 | 0.006 |
Gender (Male/ Female) | 64/20 (76.2%/23.8%) | 137/31 (78.7%/17.8%) | 3.36 | 0.07 |
Marital status | 1.06 | 0.59 | ||
Single | 45/75 (60.0%) | 104/160 (65.0%) | ||
Married | 9/75 (12.0%) | 21/160 (13.1%) | ||
Divorced | 21/75 (28.0%) | 35/160 (21.9%) | ||
Weight (kg) | 62.0 ± 10.3 | 67.8 ± 16.6 | 9.40 | 0.002 |
Blood pressure | ||||
Systolic pressure | 122.5 ± 7.2 | 125.5 ± 8.0 | 7.98 | 0.005 |
Diastolic pressure | 77.3 ± 5.7 | 76.6 ± 6.0 | 0.81 | 0.37 |
Smoker/non-smoker | 11/65 | 92/74 | 35.8 | 0.000 |
Duration of illness (years) | 29.4 ± 11.0 | 27.4 ± 10.3 | 2.09 | 0.14 |
Age of onset (years) | 25.4 ± 7.9 | 23.8 ± 7.3 | 2.06 | 0.15 |
Comorbid physical diseases | 43 (48.8%) | 44/164 (26.8%) | 11.9 | 0.001 |
Antipsychotics | 14.1 | 0.03 | ||
Olanzapine | 18 (21.4%) | 16 (9.2%) | ||
Risperidone | 16 (19.0%) | 45 (25.9%) | ||
Clozapine | 15 (17.9%) | 55 (31.6%) | ||
Quetiapine | 13 (15.5%) | 18 (10.3%) | ||
Aripiprazole | 11 (13.1%) | 17 (9.8%) | ||
Ziprasidone | 4 (4.8%) | 5 (2.9%) | ||
Typicals | 7 (8.3%) | 18 (10.3%) | ||
Antipsychotic dose (mg/d) (chlorpromazine equivalents) | 264.4 ± 160.8 | 226.9 ± 152.8 | 3.16 | 0.08 |
- Citation: Sheng HW, Wang HG, Wang CZ, Wu J, Huo LJ, Wang RX, Zhou YJ, Zhang XY. Prevalence and clinical characteristics of COVID-19 in inpatients with schizophrenia in Wuhan, China. World J Psychiatry 2022; 12(1): 140-150
- URL: https://www.wjgnet.com/2220-3206/full/v12/i1/140.htm
- DOI: https://dx.doi.org/10.5498/wjp.v12.i1.140